Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_4
1
33%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_2

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

NCT06976619
completedphase_4

The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence

NCT02678377
completednot_applicable

Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients

NCT03435185

Clinical Trials (3)

Showing 3 of 3 trials
NCT06976619Phase 2

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

Recruiting
NCT02678377Phase 4

The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence

Completed
NCT03435185Not Applicable

Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3